Summary There is abundant evidence that inhibitors of prostaglandin (PG) 3.6nM; PGI2: Bmax = 325 ± 194 fmol mg-protein, Kd = 6.8 ± 7.1nM) were significantly (P < 0.01) diminished.
Prostaglandins (PGs) are considered to play an important role in the regulation of tumour cell growth and metastases formation (Honn et al., 1981) . In recent years several studies have shown that inhibitors of PG biosynthesis, including indomethacin, may improve the therapeutic effect of chemo- (Powles et al., 1978) , immuno- (Chun & Hoffman, 1987) and/or radiotherapy (Furuta et al., 1988a) regimens of some tumours. However, whereas indomethacin remarkably increased tumour cell radioresponse, it had only minimal effect on the radioresponse of normal tissues such as hair follicles, jejunum or hematopoietic tissue (Furuta et al., 1988a) . Furthermore, the response to indomethacin treatment was dependent on the ability of the tumour to produce PGs, mainly PGE2 and PGI2 (Furuta et al., 1988b) . Apart from the fact that the mechanisms by which indomethacin potentiates tumour radioresponse are still unclear to date, it appears that an increased tumour response might be achieved by lowering PGs in the tumour. This, however, would imply that PGs are not radioprotective agents as has been suggested by Hanson & Ainsworth (1985) or Walden et al. (1987) . Milas and coworkers (1990) have also found that potentiation of the tumour radioresponse induced by indomethacin is more significant when it is given after rather than before irradiation. Beside recent reports on the dependence of indomethacin-augmented radioresponse on immunocompetence of the tumour host (Milas et al., 1990) , another possibility for PG action on tumour cells would be radiosensitisation by PGs. Moreover, one has also to bear in mind that the PG production may be remarkably different among various tumours (Malachi et al., 1981; Ziboh et al., 1981) .
PGs exert their effects after interaction with specific cell surface receptors (Virgolini et al., 1992) . We have demonstrated in human thyroid cancer (Virgolini et al., 1988) and hepatomas (Virgolini et al., 1989) that the number of PG receptors significantly (P<0.001) correlates with the cellular differentiation of the tumour. In these studies we found that high differentiated cancers seems to possess a higher PG receptor density than do anaplastic or less differentiated cancers. Furthermore, patients with a higher PG receptor density might have a better clinical prognosis. We have now used a similar receptor assay and have characterised the PG receptor on cultured human hypernephroma cells. These cells were shown to produce an increased amount of PGs of the E-series as compared with normal tissue (Cummings & Robertson, 1977) . Furthermore, hypernephroma cells are relatively radiosensitive to high-dose radiation therapy (Halperin & Harisindis, 1983; Lang & deKernion, 1981 (Diereck et al., 1991) . If there were only cytokeratin-positive cells, the cell culture was used for combined testing in the second passage. Cultures which were contaminated with cytokeratin-negative cells were further propagated and checked again when the cells became confluent. If there were still cytokeratin-negative cells after the fourth passage, the cell line was excluded from the test.
Cells from each cell line (one from each patient) were divided into four groups:
(1) Control group; (2) ASA-treated group: cells were cultured in the presence of ASA (Bayer, Leverkusen, Germany; concentration 0.5 mg-6 cells ml-' medium for 24h); (Wandl et al., 1989) .
Binding studies PG receptor binding studies were carried out according to the methodology described previously (Virgolini et al., 1992) . All assays reported here were performed approximately 2 h after irradiation. Briefly, the cells (4-6 x 106 cells in each group) were washed twice in assay buffer containing 50 mM Tris-HCI (pH 7.5), 5 mM MgCl2, 1 mM CaC12, 0.1 M NaCI and centrifuged at 500g for O min at 4°C (Beckman J-6B Centrifuge, Munchen, Germany). The pellet was suspended in 4°C assay buffer at a protein concentration of approximately 300 yg membrane protein ml-' (200-420 fg ml-') as determined by the assay kit provided by Bio-Rad Laboratories (Coomassie Brilliant Blue G-250, Richmond, CA). In preliminary experiments the time course of binding as well as the dependency of binding on temperature was studied. Based on the results of these experiments all further incubations were performed at 4°C for 50 min to ensure equilibrium.
In saturation experiments hypernephroma cells (300 jg protein ml-') were incubated either with increasing concentrations of 3H-iloprost (a chemically stable PGI2-analog (Skuballa & Vorbruggen, 1983) ; specific activity 14.7 Ci mmol '; radiochemical purity 98.7%; 0.5-I00 nM), 3H-PGE, (specific activity 42 Ci mmol 1; radiochemical purity 97.5%; 0.5-100 nM) or 3H-PGE2 (specific activity 143 Ci mmol '; radiochemical purity 97.5%; 0.5-98 nM), respectively, in order to determine total binding (TB). In separate incubation series these increasing concentrations of 3H-iloprost, 3H-PGE, or 3H-PGE2 were incubated in the presence of the same unlabelled agonist to determine nonspecific binding (NSB). Specific binding (SB) was expressed as the difference of total and nonspecific binding. In displacement studies cells (300 jig ml-' protein) were incubated with 15 nM of 3H-PGEI, 3H-PGE2 or 3H-iloprost in the absence (TB) and presence of increasing concentrations (10--10-M) of unlabelled agonist (NSB).
After incubation for 50 min at 4°C the reaction was diluted rapidly with 4 ml of 4°C assay buffer and filtered through a Whatman GF/B filter (Whatman Inc., Clifton, NY) under reduced pressure (-60 kPa). The filters were then dried, transferred into scintillation vials (Packard, Downers Grove, IL) and taken up into 10 ml scintillation fluid (Pico-Flour TM30, Packard). The radioactivity in the samples was counted for 5 min in a liquid scintillation counter (LKB Wallace, 1215 Rackbeta, Finland RIA accord- ing to the manufacturer's description (Amersham) . Briefly, the samples were mixed with 251I-cAMP and rabbit anticAMP serum and incubated for 3 h at 4°C. The antibodybound cAMP was then extracted with a donkey anti-rabbit antibody, which was coated onto magnetisable polymer particles. These were mixed and left to react with the antibodies for 10 min at 25°C. The antibody-bound fraction was obtained with a magnetic separator (Amerlex-M Separator, Amersham) and the activity was determined by a gamma counter (Riastar, Packard). The intra-assay variability was 3.5 ± 1.3% and the inter-assay 5.6 ± 2.3%.
Radiothinlayer chromatography
The cells (4-6 x 106 in each group) were resuspended in 50 mM Tris-HCI buffer (pH 7.5) and incubated with 0.25 LCi '4C-arachidonic acid (AA) (New England Nuclear, Boston, MA; specific activity 54.5 mCi mmol-'; radiochemical purity 96.3%) for 30 min in a shaking water bath (37°C). The reaction was stopped with 1 M HCI. After centrifugation at 5000 g (10 min, 4°C) the supernatant was extracted with ethylacetate (Merck, Germany) Specific 3H-iloprost, 3H-PGE, and 3H-PGE2 binding was only slightly dependent on temperature and was insignificantly lower at 37°C and at 22°C than at 4°C. 3H-iloprost, 3H-PGE1 and 3H-PGE2 binding to human hypernephroma cells could be displaced by unlabelled iloprost, PGEI and PGE2, respectively. In 3H-iloprost binding studies the concentrations of unlabelled iloprost, PGE,, PGE2 for causing half maximal inhibition (IC50) were 81± 25 x 10-9 M, 12±6x 10-8 M and 9±3x 10-6 M, respectively. The IC50 values were 40 ± 10 x 10-9 M for PGEI, 86 ± 20 x 10-9 M for iloprost, and 85 ± 26 x 10-6 M for PGE2 in 3H-PGE, binding experiments, and amounted to 42 ± 9 x 10-9 M for PGE2, 4±2x 10-6 M for PGE1 and 30± 7 x 10-6 M for iloprost in 3H-PGE2 binding studies (Figure 2a-c) .
Saturation of 3H-PG binding to human hypernephroma cells was studied by incubating increasing concentrations of ligand in the absence and presence of an excess of the same unlabelled agonist. Binding was saturable and indicated a single class of high affinity binding sites for all three ligands within the ligand range studied (Figure 3a-b) . After preincubation of the cells with ASA (group 2) a significantly (P<0.01) increased capacity to bind the PGs was found. The respective binding data are given in Tables I-III significant decrease in 3H-PG-receptors: 3H-iloprost receptor decreased to 325 ± 194 fmol mg-' protein (P<0.001), 3H-PGE1-receptors to 266 ± 153 fmol mg-' protein (P < 0.001), and 3H-PGE-receptors to 148 ± 66 fmol mg-' protein (P < 0.01). After pre-treatment with ASA the decrease induced by irradiation was much less pronounced (P>0.05) (3H-iloprost receptors: 766 ± 452 fmol mg-' protein, 3H-PGE,-receptors: 699 ± 240 fmol mg-' protein, 3H-PGE2-receptors: 287 ± 114 fmol mg-' protein).
Effect of PGs on cAMP-formation There was no significant difference in basal values between control (30.1 ± 10.5 pmol mg -') and ASA-treated group (28.0 ± 11.5 pmol mg-' protein). However, the basal values of control group irradiated (17.6 ± 8.9 pmol mg-' protein) and of ASA-treated group irradiated (15.8 ± 6.1 pmol mg-' protein) were significantly (P<0.001) lower as compared to the control group.
Iloprost, PGE, and PGE2 significantly (P<0.01) stimulated cAMP-production in all four groups dose-dependently. However, the half maximal effective doses (ED50) (Virgolini et al., 1988 ) and E human hepatocellular cancer (Virgolini et al., 1989 ). We -a Al / (Virgolini et al., 1988 (Virgolini et al., , 1989 Bm.: binding capacity in fmol mg-' protein; Kd: (dissociation constant) in nM; not investigated. ap < 0.05, bp < 0.0 , Cp < 0.001, vs the control group (without irradiation). dp <0.05, vs the irradiated control group. Significant (P<0.05) increase in 3H-iloprost receptors expressed on hypernephroma cells was found after pre-treatment with ASA which also led to a significant (P < 0.05) increase in the binding affinity. Irradiation caused significant (P<0.001) depression of 3H-iloprost receptors while the binding affinity remained unchanged.
Irradiated ASA-pretreated cells had a similar binding capacity to the plane control group and a significantly (P < 0.05) higher one as compared with the irradiated control group. most cells 3H-PGE, as well as 3H-iloprost seem to bind to two binding classes with different affinity (Virgolini et al., 1992) Recently a number of studies in murine tumours have shown that indomethacin significantly increases radioresponse of tumours which produce PGs (Furuta et al., 1988a (Furuta et al., , 1988b . Initially it was proposed that the augmentation of radioresponse induced by indomethacin could be due to lowering PGs in tumour tissues. The effects of PGs on radioprotection are, however, not clear: some authors reported that PGs might act as radioprotectors (Hanson & Ainsworth, 1985; Walden et al., 1987) , whereas others (Milas et al., 1990) proposed an opposite effect.
PGs exert their effects through interaction with specific cell surface receptors. There is little information about PG receptor expressed by tumour cells after radiotherapy. We were now able to show that although the number of PG binding sites was significantly diminished after irradiation with 'Co, no significant change in the number of PG binding sites was found for human hypernephroma cells after pre-incubation with ASA. The results indicate that the PG synthesis inhibitor ASA could protect against an irradiation effect on PG receptors, modifying the radioresponse of human hypernephroma cells. The presence of PGs as well as PG ri human hypernephroma cells suggests . tumour growth and possibly its metastas already been reported that certain syndro hypernephromas such as the osteolytic secutive hypercalcaemia might result fror hypernephroma cells (Robertson et al., Robertson, 1977) . Furthermore, increases tumours has been associated with a inhibitors of PG synthesis including ASA were reported to retard tumour growth mation (Lynch et al., 1978; Bennett,, 19 cAMP is a second messenger mediating the actions of PGs and also connected with normal and malignant cell proliferation. It is likely that changes in intracellular cAMP-1.0 10 100 production due to PG stimulation may greatly influence tumour cell growth and even metastases formation (Heidrick & Ryan, 1971; Sheppard, 1972) . However, both reduced ation on cAMP-pro cAMP levels (Malachi et al., 1981; Goldberg et al., 1975;  by different concen- Stevens et al., 1978) and elevated cAMP contents (Minton et 
